<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4032892/" ref="ordinalpos=1337&amp;ncbi_uid=6202169&amp;link_uid=PMC4032892" image-link="/pmc/articles/PMC4032892/figure/F1/" class="imagepopup">Figure 1.  From: Targeting the PI3K/mTOR <span class="highlight" style="background-color:">Pathway</span> in Pediatric Hematologic Malignancies. </a></div><br /><div class="p4l_captionBody"><b>Schema of PI3K/mTOR and other oncogenic signaling pathways in hematologic malignancies</b>. Inhibitors (i) of these signaling proteins under current preclinical or clinical study with potential therapeutic relevance for pediatric hematologic malignancies are delineated. Red = inhibitors of PI3K/mTOR pathway signal transduction protein(s).</div></div>